MGUS

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
星期四, 四月 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

The International Myeloma Foundation Launches the Iceland Cycling Expedition: A Fundraiser to Advance the Goals of the iStopMM Project and the IMF’s Robust Array of Research Initiatives

Retrieved on: 
星期二, 二月 13, 2024
Knowledge, African Americans, Bone marrow, Research, Multiple myeloma, SMM, ICE, MGUS, IMF, International Myeloma Foundation, Genetic distance, University, Genetics, Blue, Blue Lagoon, DNA, Cryptocurrency

The ICE biking tour is an inaugural signature IMF Myeloma Cures fundraiser, with the goal of highlighting IMF’S diverse and robust research portfolio.

Key Points: 
  • The ICE biking tour is an inaugural signature IMF Myeloma Cures fundraiser, with the goal of highlighting IMF’S diverse and robust research portfolio.
  • Durie is elated that the Iceland Cycling Expedition will be inaugurated in Iceland—the home of the iStopMM Research Project.
  • To apply for this exciting expedition or to make donations, visit the IMF Iceland Cycling Expedition fundraiser.
  • The International Myeloma Foundation is grateful to Sanofi, a long-time and unwavering supporter of the IMF, for sponsoring the inaugural Iceland Cycling Expedition.

International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting

Retrieved on: 
星期五, 一月 12, 2024
Projection screen, MGUS, Risk, Research, Body mass index, Multiple myeloma, Smoking, IMF, Thrombosis, BSRI, SMM, Sense, Conference, Abstract, ASH, Treatment, Abstract (summary), Cosmetics

( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )

Key Points: 
  • ( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )
    A Media Snippet accompanying this announcement is available by clicking on this link.
  • In a recent Ask Dr. Durie video , IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M.
  • Durie discusses the iStopMM Project’s purpose in doing the large-scale screening study and the advantages that come with early screening.
  • You may also access the complete list of 2023 ASH Abstract Achievement Awardees on the ASH website.

Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Retrieved on: 
星期一, 十二月 11, 2023
Patient, Bone marrow, MGUS, Cyclophosphamide, IND, Prevalence, Disease, NYHA, BCMA, MD, Daratumumab, Society, Standard of care, AL amyloidosis, ASH, Dexamethasone, LOS, Bortezomib, Hematopoietic stem cell transplantation, Treatment, CRS, Heart failure, Pharmaceutical industry

“We continue to be encouraged by NXC-201’s 100% overall response rate, including in this 10th relapsed/refractory AL amyloidosis patient.”

Key Points: 
  • “We continue to be encouraged by NXC-201’s 100% overall response rate, including in this 10th relapsed/refractory AL amyloidosis patient.”
    “We believe NXC-201 is the first and only CAR-T in clinical development for AL amyloidosis.
  • With our recent IND clearance, we are thrilled to be now activating sites to bring this first-of-a-kind study to U.S. relapsed/refractory AL Amyloidosis patients,” said Ilya Rachman, M.D., Ph.D., Executive Chairman of Nexcella.
  • Patients were infused with CAR+T cells at doses of 150 x 106 (n=1), 450 x 106 (n=2), and 800 x 106 (n=7).
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Retrieved on: 
星期一, 十二月 11, 2023
Patient, Bone marrow, MGUS, Cyclophosphamide, IND, Prevalence, Disease, NYHA, BCMA, MD, Daratumumab, Society, Standard of care, AL amyloidosis, ASH, Dexamethasone, LOS, Bortezomib, Hematopoietic stem cell transplantation, Treatment, CRS, Heart failure, Pharmaceutical industry

LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA) at an oral presentation by study investigator Moshe E. Gatt, MD at the 65th American Society of Hematology (ASH) Meeting being held in San Diego, CA. The updated results include follow-up and clinical data from one new patient. All patients were relapsed/refractory to standard-of-care Dara-CyBorD (daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone) and had experienced a median of 6 prior lines of therapy that failed to stop worsening of disease prior to receiving NXC-201.

Key Points: 
  • “We continue to be encouraged by NXC-201’s 100% overall response rate, including in this 10th relapsed/refractory AL amyloidosis patient.”
    “We believe NXC-201 is the first and only CAR-T in clinical development for AL amyloidosis.
  • With our recent IND clearance, we are thrilled to be now activating sites to bring this first-of-a-kind study to U.S. relapsed/refractory AL Amyloidosis patients,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma.
  • Patients were infused with CAR+T cells at doses of 150 x 106 (n=1), 450 x 106 (n=2), and 800 x 106 (n=7).
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis

CARsgen Announces Formation of its Clinical Advisory Board

Retrieved on: 
星期一, 十一月 20, 2023
Dexamethasone, Experiment, Teaching hospital, Patient, Strategic planning, Bortezomib, Vall d'Hebron University Hospital, Cancer, Ernest Beutler, TCO, Doctor of Philosophy, Knowledge, Axicabtagene ciloleucel, University of Miami, Multiple myeloma, Douglas E. Lynch, R.J. Corman Railroad Group, University, ESMO, Harvard Medical School, Regorafenib, Biomarker, Principal, Translation, Vall, MD Anderson Cancer Center, Lenalidomide, Therapy, National Cancer Institute, Dana–Farber Cancer Institute, MGUS, Publication, Drug development, NCI-designated Cancer Center, The Lancet, Research, Lymphoid leukemia, NCI, CD19, MRD, FDA, MD, Survival, Lymphoma, Pharmaceutical industry, Daratumumab, Medicine, Immunotherapy

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.

Key Points: 
  • SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.
  • This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.
  • "As we embark on this exciting journey to advance our differentiated CAR T-cell therapies, I am delighted to welcome our esteemed Clinical Advisory Board members.
  • The formation of this Clinical Advisory Board marks a significant step forward for CARsgen as it continues to pioneer CAR T-cell therapies with the potential to transform cancer treatment.

Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Retrieved on: 
星期一, 十一月 6, 2023
AL, Treatment, MD, AL amyloidosis, Society, ASH, LOS, MGUS, Exposition, Patient, Pharmaceutical industry, Amyloidosis

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq:IMMX) (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “NXC-201 is the only CAR-T being studied as a treatment for AL amyloidosis patients who relapsed, or are refractory to, 4-drug combination daratumumab-CyBorD,” said Ilya Rachman, MD PhD, Executive Chairman of Nexcella.
  • “NXC-201 attacks the root cause of AL Amyloidosis: disease-causing plasma cells, representing a potential one-time treatment option.”
    “30,000 – 45,000 patients in the United States and Europe are living with AL Amyloidosis, for many of whom there are no additional approved treatment options beyond Dara-CyBorD,” said Gabriel Morris, President of Nexcella.
  • “We are pleased to present our progress on advancing NXC-201 at the upcoming 65th annual ASH meeting in San Diego.”
    65th ASH Annual Meeting and Exposition, San Diego, CA
    Session Name: 654.
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Retrieved on: 
星期一, 十一月 6, 2023
AL, Treatment, MD, AL amyloidosis, Society, ASH, LOS, MGUS, Exposition, Patient, Pharmaceutical industry, Amyloidosis

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “NXC-201 is the only CAR-T being studied as a treatment for AL amyloidosis patients who relapsed, or are refractory to, 4-drug combination daratumumab-CyBorD,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma.
  • “NXC-201 attacks the root cause of AL Amyloidosis: disease-causing plasma cells, representing a potential one-time treatment option.”
    “30,000 – 45,000 patients in the United States and Europe are living with AL Amyloidosis, for many of whom there are no additional approved treatment options beyond Dara-CyBorD,” said Gabriel Morris, Chief Financial Officer of Immix Biopharma.
  • “We are pleased to present our progress on advancing NXC-201 at the upcoming 65th annual ASH meeting in San Diego.”
    65th ASH Annual Meeting and Exposition, San Diego, CA
    Session Name: 654.
  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis

Moving Mountains for Multiple Myeloma® Program to Trek Through Alaska, July 23-29

Retrieved on: 
星期四, 七月 20, 2023
Fund Raising, Foundation, Philanthropy, GSK, Multiple Myeloma Research Foundation, Friends, Multiple myeloma, Bone marrow, Research, MGUS, Patient, Moving Mountains, Nursing, B cell, Diagnosis, Caregiver, Disease, MMRF, Pharmaceutical industry

The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.

Key Points: 
  • The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.
  • Since MM4MM began with its first trek in 2016, the program has raised over $3 million for multiple myeloma research.
  • The upcoming Alaska trek will include an extraordinary group of multiple myeloma patients, caregivers, friends and family members, nurses, and team members from the organizing partners.
  • More than 50 years ago, her father passed away from multiple myeloma, and just two years ago, her husband, Ed, was diagnosed with smoldering multiple myeloma.

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Retrieved on: 
星期三, 十二月 14, 2022
Biotechnology, Probability, Inflore, Dana–Farber Cancer Institute, Lymphatic system, PMID, BM, MD, Kaplan–Meier estimator, Society, Research, Hematology, Patient, Clinical, LDT, Multiple myeloma, Chromosomal translocation, Mortality, System, FDA, HIV disease progression rates, Disease, Incidence, Personal computer, Pathology, Liquid biopsy, Cell, Bone marrow, CTC, Risk, Chinese, Safety, CMMC, Resource, B cell, SMM, MSB, Silicon, Blood, ASH, MGUS, Medical imaging, Pharmaceutical industry, Medical device

HUNTINGDON VALLEY, Pa., Dec. 14, 2022 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology. This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.

Key Points: 
  • This study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery1.
  • This type of blood cancer forms in plasma cells (PCs) located in the bone marrow (BM).
  • 1Dutta A, Alberge J-B, et al, MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology, Cancer Discov CD-22-0482.
  • * The Circulating Multiple Myeloma Cell (CMMC) test is a CLIA-accredited laboratory developed test from Menarini Silicon Biosystems in USA.